A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician’s choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients
BRAVO is a phase III study that was designed to compare the efficacy and safety of niraparib vs standard of care in patients with HER2-negative previously treated advanced/metastatic breast cancer with a germline BRCA mutation.
Between February 25, 2014 and March 29, 2017, 758 patients were registered at 106 sites in 14 countries, of whom 215 patients were randomized: 141 patients to niraparib and 74 patients to physician’s choice.
BRAVO is a BIG co-lead study sponsored by Tesaro (now GSK) and conducted in partnership with the European Organisation for Research and Treatment of Cancer (EORTC).
Recruitment opened in January 2014 and closed in March 2017.
BRAVO was terminated in March 2017 due to futility. The reason for closure and results are described in a publication by Turner et al. (please see ‘Related publication’ section below).
Tesaro (now GSK) provided funding and drug for this study, which was run according to BIG’s Principles of Research Conduct.
CALL FOR DATA ONLY RESEARCH PROPOSALS
Research project proposals (RPPs) requesting access to data only can be submitted at any time. For more information, please refer to the BRAVO Policy for Access to Study Data and Biological Samples. Applicants must fill out the submission form, providing all required information per the instructions on the form, and submit it to the BRAVO RPP Administrator: email@example.com; Vanessa.CorreiaDeNobrega@bigagainstbc.org.
Please feel free to share this information with colleagues and collaborators who might be interested in submitting proposals!